HRT vs GLP-1 for menopause weight loss: which is right for you?

Most women gain five to fifteen pounds across the menopause transition, and the weight tends to settle around the midsection in ways it never did before. Two of the most discussed treatments — Hormone Replacement Therapy (HRT) and GLP-1 medications like semaglutide and tirzepatide — work in completely different ways. Understanding the difference matters, because the right choice depends on what is actually driving the weight gain for you.

Why weight gain happens in menopause

Three things shift at once. First, estrogen falls, which changes where the body stores fat — visceral (abdominal) fat increases even when total weight stays the same. Second, lean muscle mass declines by roughly 3–8% per decade after 40, which lowers resting metabolic rate. Third, insulin sensitivity worsens, making the body more prone to storing carbohydrate as fat. Sleep disruption from hot flashes compounds all three by raising cortisol and appetite-driving hormones like ghrelin. Weight gain in midlife is not a willpower problem — it is a hormonal and metabolic one.

What HRT does for weight and body composition

Hormone Replacement Therapy does not directly cause weight loss, and the randomized trials are clear that it does not cause weight gain either. What it does do is shift body composition in a favourable direction: women on estradiol tend to accumulate less visceral fat, preserve more lean muscle, and maintain better insulin sensitivity than untreated peers. HRT can also reduce hot flashes and improve sleep disrupted by night sweats, which can make consistent exercise and good eating easier to sustain. The weight effect is indirect but real: HRT removes the headwinds.

What GLP-1 medications do

GLP-1 receptor agonists — semaglutide, tirzepatide, and liraglutide — mimic a gut hormone that signals fullness to the brain and slows gastric emptying. The result is a meaningful reduction in appetite and food noise, improved glucose control, and steady weight loss. In the STEP 1 and SURMOUNT-1 trials, average weight loss was about 15% with semaglutide and up to about 20% with the highest tirzepatide dose over roughly 68–72 weeks, alongside lifestyle intervention; individual results vary. These are pharmacologically driven effects that work regardless of menopausal status, but they are especially powerful for women whose midlife weight gain is being driven by appetite dysregulation and insulin resistance.

Side-by-side: how they compare

• Mechanism — HRT restores estrogen and progesterone; GLP-1 mimics a gut hormone that suppresses appetite
• Primary purpose — HRT treats menopause symptoms; GLP-1 treats obesity and type 2 diabetes
• Weight effect — HRT shifts composition (less visceral fat, more muscle preservation); GLP-1 produced average losses of about 15–20% in trials
• Symptom relief — HRT is the most effective treatment for hot flashes and night sweats and treats vaginal dryness, and it may help sleep disrupted by night sweats; GLP-1 is not a menopause treatment
• Bone protection — HRT actively protects bone density; GLP-1 alone does not, and rapid weight loss can reduce bone mass
• Side effects and risks — HRT: breast tenderness and spotting are common early on; serious risks include blood clots (higher with oral estrogen than with patches or gels), stroke, and, with combined estrogen-progestin, a small increase in breast cancer risk; GLP-1: nausea, constipation, reflux, potential muscle loss, and less common risks such as gallbladder problems and pancreatitis
• Duration — HRT often continued for years; GLP-1 typically required long-term to maintain weight loss

When treating menopause symptoms first may make sense

If hot flashes, night sweats, or sleep disruption are present alongside the weight change, it is reasonable to discuss whether treating those symptoms first makes sense for you. Treating the hormonal driver often improves the metabolic environment enough that lifestyle changes — strength training, protein-forward eating, sleep — actually start to work again. Some women find that treating symptoms alongside consistent resistance training helps them stop the slow drift upward in weight.

When a GLP-1 makes sense

A GLP-1 is a strong fit when appetite and food preoccupation are the dominant problem, when BMI is in the obesity range, when insulin resistance or pre-diabetes is documented, or when HRT plus lifestyle has not been enough. GLP-1s are also useful for women who cannot take HRT for medical reasons. The trade-off is that GLP-1 weight loss includes some lean mass loss, which matters more in midlife than at any other life stage — so protein intake and strength training become non-negotiable.

When the combination works best

For some women with significant weight gain and active menopause symptoms, HRT and a GLP-1 are used together, but evidence on the combination comes mainly from small observational studies, not randomized trials. HRT can help protect bone density during weight loss and treats symptoms a GLP-1 does not. The GLP-1 provides the appetite control and meaningful weight loss that HRT alone does not deliver. Used together, the two address different pieces of the same problem.

What to do before starting either

• Ask your clinician which tests make sense for you. Menopause is usually diagnosed from symptoms after 45 rather than from FSH or estradiol levels, while tests such as A1c, a lipid panel or thyroid function may be relevant
• Discuss personal and family history of breast cancer, blood clots, and cardiovascular disease with a menopause-trained clinician
• Set up resistance training and adequate protein (1.2–1.6 g per kg per day) before starting a GLP-1 to protect lean mass
• Plan for monitoring — symptom response on HRT at 6–8 weeks; weight, glucose, and side effects on a GLP-1 monthly

The bottom line

HRT and GLP-1s are not competing therapies — they treat different problems that often overlap in midlife. If menopause symptoms are present, a clinician can help you decide whether to address them first, and when to reassess weight. If appetite and significant excess weight are the central issue, a GLP-1 may be the right tool. For many women, the answer is both, used together under the care of a clinician who understands menopause medicine.

Medically reviewed by Kindr Health Clinical Team
Kindr Health Inc. — Editorial & Clinical Team, led by Kevin Wolfe, CMO
NPI 1609792902 · Last reviewed: June 10, 2026